Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00051025
Status:
COMPLETED
Last Update Posted:
2012-07-13
First Post:
2002-12-31
Brief Title:
Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkins Lymphoma NHL
Sponsor:
Eisai Inc
Organization:
Eisai Inc
Study Overview
Official Title:
A Randomized Multicenter Phase II Evaluation of ONTAK Denileukin Diftitox in Patients With Previously Treated Indolent B-Cell Non-Hodgkins Lymphoma
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to look at the safety and effectiveness of ONTAK in previously treated patients with NHL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None